Xenocor, Inc., a developer of advanced surgical visualization and minimally invasive surgery technologies, today announced the appointment of David McNally as Chief Executive Officer. McNally brings more than 40 years of entrepreneurial and executive experience in the medical device industry, including leadership roles in product development, commercialization, and global expansion of innovative therapies, surgical devices and technologies.
In conjunction with McNally’s appointment, the company also announced two executive leadership appointments. Antony Watson has been appointed Chief Commercial Officer, and David Van Ness has been appointed Chief Technology Officer.
“David’s deep experience leading medical device organizations and commercializing innovative surgical technologies makes him an outstanding choice to guide Xenocor through its next phase of growth,” said Dinesh Patel, PhD, Co-founder and Executive Chairman of the Board of Xenocor. “As Xenocor expands the commercialization of its Saberscope™ platform, David’s leadership will help accelerate adoption of technologies that improve surgical visualization, operating room efficiency, and minimally invasive surgical procedures.”
McNally has spent more than four decades working across the medical device sector in executive leadership roles spanning research and development, engineering, operations, commercialization, and corporate strategy. Throughout his career, he has helped build and scale companies developing technologies that improve surgical performance and patient outcomes in abroad array of clinical applications.
“I am honored to join Xenocor at such an exciting time in the company’s evolution,” said McNally. “The company’s recently FDA 510(k)-cleared Saberscope™ platform represents an important innovation in surgical visualization by delivering high-quality imaging in a cost-effective streamlined system designed to expand access to minimally invasive surgery. I look forward to working closely with Antony, David, and the entire team to accelerate adoption of Xenocor’s technology and continue advancing surgical imaging solutions that support surgeons and improve patient care.”
As Chief Commercial Officer, Watson will lead Xenocor’s global commercial strategy, including sales, marketing, distribution partnerships, and customer engagement initiatives as the company expands market adoption of its Saberscope™ surgical visualization and endoscopic imaging system.
As Chief Technology Officer, Van Ness will lead Xenocor’s engineering and product development initiatives, overseeing continued advancement of the company’s imaging technologies and future generations of the Saberscope™ platform for minimally invasive and laparoscopic surgical procedures.
“These leadership appointments position Xenocor for growth and innovation,” McNally added. “Antony and David have already played critical roles in the development of our technology, and their leadership will be instrumental as we expand the reach of SaberScope™ and introduce additional surgical visualization and endoscopic imaging solutions.”